AEB1102 for Arginase I Deficiency (AEB1102 Trial)

"AEB1102 has been assigned a preliminary safety score of 2, as there is evidence that it can be consumed without risk but nothing yet to suggest its efficacy."

"At this time, participants can join the trial at 5 different sites around North America, such as New york City, Dallas and Toronto. To reduce travel costs to a minimum, please select a clinical centre near your residence."

"Presently, there are two AEB1102 studies in the process of being conducted - one is already at Phase 3. Although much of the research activity for this medication occurs near Porto, California, trial sites can be found across 40 locations nationwide."

"At the current time, this investigation is not in need of any more enrollees. The protocol was initially uploaded on December 7th 2017 and had its most recent update on July 22nd 2022. For those exploring other medical research projects, there are two separate studies searching for patients suffering from hyperargininemia and 2 trials involving AEB1102 actively recruiting test subjects."

"Presently, there are two active trials for AEB1102 spanning 8 different nations and 21 cities. Aeglea Biotherapeutics commenced the initial trial in 2017 with 14 patients; it successfully achieved Phase 2 drug approval status before 4 additional studies were conducted since then."

"This clinical trial is not currently open for new enrolments. It was initially posted on December 7th 2017, and its most recent update took place on July 22nd 2022. To those exploring other studies, there are presently two hyperargininemia trials actively recruiting participants, as well as two AEB1102 research projects in search of patients."